Brought to you by 
Insys Therapeutics goes public on second try; nets $34.2mm
05 Jun 2013
Executive Summary
After filing to go public in March 2011, Insys Therapeutics Inc. (cancer, neurology, and gastrointestinal pharmaceuticals) has netted $34.2mm through the sale of 4.6mm common shares (including the overallotment) at $8. Last month the firm had proposed selling 4mm shares between $16-18 each, then weeks later lowered the price to $8-10. This was Insys's second IPO attempt; the first try was halted in 2007 due to market conditions.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Insys Therapeutics goes public on second try; nets $34.2mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice